GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » POINT Biopharma Global Inc (NAS:PNT) » Definitions » Quick Ratio

POINT Biopharma Global (POINT Biopharma Global) Quick Ratio : 9.14 (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is POINT Biopharma Global Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. POINT Biopharma Global's quick ratio for the quarter that ended in Sep. 2023 was 9.14.

POINT Biopharma Global has a quick ratio of 9.14. It generally indicates good short-term financial strength.

The historical rank and industry rank for POINT Biopharma Global's Quick Ratio or its related term are showing as below:

PNT' s Quick Ratio Range Over the Past 10 Years
Min: 2.4   Med: 10.9   Max: 32.04
Current: 9.14

During the past 3 years, POINT Biopharma Global's highest Quick Ratio was 32.04. The lowest was 2.40. And the median was 10.90.

PNT's Quick Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.595 vs PNT: 9.14

POINT Biopharma Global Quick Ratio Historical Data

The historical data trend for POINT Biopharma Global's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

POINT Biopharma Global Quick Ratio Chart

POINT Biopharma Global Annual Data
Trend Dec20 Dec21 Dec22
Quick Ratio
2.40 30.56 6.66

POINT Biopharma Global Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.84 6.66 5.58 10.51 9.14

Competitive Comparison of POINT Biopharma Global's Quick Ratio

For the Biotechnology subindustry, POINT Biopharma Global's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


POINT Biopharma Global's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, POINT Biopharma Global's Quick Ratio distribution charts can be found below:

* The bar in red indicates where POINT Biopharma Global's Quick Ratio falls into.



POINT Biopharma Global Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

POINT Biopharma Global's Quick Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Quick Ratio (A: Dec. 2022 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(530.823-0)/79.738
=6.66

POINT Biopharma Global's Quick Ratio for the quarter that ended in Sep. 2023 is calculated as

Quick Ratio (Q: Sep. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(353.247-0)/38.666
=9.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


POINT Biopharma Global  (NAS:PNT) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


POINT Biopharma Global Quick Ratio Related Terms

Thank you for viewing the detailed overview of POINT Biopharma Global's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


POINT Biopharma Global (POINT Biopharma Global) Business Description

Traded in Other Exchanges
N/A
Address
4850 West 78th Street, Indianapolis, IN, USA, 46268
POINT Biopharma Global Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Its product pipeline includes PNT2002; PNT2004; PNT2003; PNT2001 and others.
Executives
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bridget A Martell director C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Joe A. Mccann director, officer: Chief Executive Officer 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Rajesh Malik director 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Gerald L. Hogue director 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
David Charles Lubner director C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472